Health Condition 1: K70-K77- Diseases of liver
Conditions
Interventions
Intervention1: VSL3�®, yogut�®: VSL3�®: 3 Cap per day and yogut�® 1Cap /day for 6 weeks
Control Intervention1: Placebo: Placebo (identical looking empty capsules) for 6 weeks
Sponsors
Amrita Institute Of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: Adult patients with ACLF being planned for liver transplant who fall within the EASL CLIF SOFA definition.
Exclusion criteria
Exclusion criteria: 1. Patients with other diseases of the gut eg: Inflammatory bowel disease. 2. Patients with malignancies other than Hepatocellular carcinoma 3. Patients with recent intake of synbiotics within last 1 month
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the role of synbiotics in patients with ACLF undergoing LDLT (Live Donor Liver Transplantation). Timepoint: Following Infectious complications within 6 months will be assessed. Blood stream infection: clinical signs of infection with a positive bacterial culture Urinary tract infection: positive urine culture with or without dysuria Intra-abdominal infection: positive drain cultures or positive cultures from per-cutaneously drained intra-abdominal collections. Respiratory infection: positive broncho alveolar lavage cultures | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse reactions due to synbiotics Timepoint: Throughout study period;morbidity and mortlityTimepoint: Throughout the study;qualitative and quantitative change in microbiota Timepoint: 0 and at 6 week | — |
Countries
India
Contacts
Public ContactDr Sudhindran S
Amrita Institute Of Medical Sciences
Outcome results
None listed